Januvia® Cancer: Know the Facts if Considering a Januvia® Lawsuit

Concern about an increased risk of Januvia cancer is growing. If you or someone you know have developed pancreatic cancer while taking or immediately after taking Januvia® for your diabetes, you should contact a pharmaceutical defect lawyer now.

About Januvia®

Januvia® (sitagliptin phosphate) is a dipeptidyl peptidase-4 (DPP-4) inhibitor in the incretin mimetic class of drugs, currently under review by the U.S. Food and Drug Administration (FDA). As an incretin enhancer, it suppresses the degradation of many peptides including GLP-1. Januvia became FDA-approved on October 16, 2006 for use in adults with Type II Diabetes. Januvia® is manufactured by Merck & Co., Inc., and in 2010 was prescribed close to six million times. The medication is also available in a combination pill (known as Janumet) that contains the drug metformin.

The Food & Drug Administration (FDA) approved Januvia® to help type-II diabetics control their blood sugar levels. Januvia® is sold in pill form. Other sitagliptin type 2 diabetes drugs include Janumet, Janumet XR, and Juvisync.

Januvia® and Pancreatic Cancer

In a study published in the online edition of the journal Diabetes, UCLA researchers found that Januvia® caused abnormalities in the pancreas that are recognized as risk factors for pancreatitis and, with time, pancreatic cancer in humans. A later study confirmed this suspicion, but conflicting information has come out of the scientific community.

While diabetics are more vulnerable to developing pancreatitis than those without the disease, it does appear that taking Januvia® can potentially increase that risk. And, if pancreatitis becomes chronic, the inflammation of the pancreas will alter its normal structure and functions.

Our defective drug lawyers believe that Merck failed to adequately warn medical practitioners and pharmaceutical consumers about the risk of serious and potentially fatal Januvia® side effects, including pancreatic cancer. If you or someone you know has taken this medication and developed cancer, you should speak with a defective drug lawyer to learn more about your legal rights.

In 2009, the FDA revised prescribing information for Januvia and Janumet (sitagliptin and metformin) to include information on reported cases of acute pancreatitis in patients using the sitagliptin drugs. Risk factors for pancreatitis can also increase the risk of pancreatic cancer.

The FDA is now reviewing new findings by academic researchers showing an increased risk of pancreatitis and pancreatic duct metaplasia (pre-cancerous cellular changes) in type 2 diabetics taking incretin mimetics, including Januvia. According to the FDA, one study found that the incretin mimetics could double the risk of acute pancreatitis.

Watts Guerra LLP Handling Largest Incretins Pancreatic Injury & Wrongful Death Docket

Watts Guerra LLP is currently handling the country’s largest incretins pancreatic cancer injury and wrongful death docket. Our lawyers have always handled pharmaceutical injury cases nationally. We are not new to this area of practice. You need a firm with experience to handle a serious injury or death case like a Januvia® lawsuit.

Mikal C. Watts is one of the most successful pharmaceutical lawyers in the country. He has handled pharmaceutical and medical device cases, including but not limited to Ortho-Evra, Vioxx, Fen Phen, Rezulin, Zyprexa and Sulzer hip implants. Mr. Watts maintains a 50,000 square foot office building with a staff of over 60 employees devoted to the handling of cases like yours. You need a firm with experience to handle a serious injury or death case like a Januvia lawsuit. Let our firm, Watts Guerra LLP, help you and your family.

Disclaimer: The images on this page of the Januvia packaging, product, and/or logo are for informational purposes; this website is neither affiliated with nor sponsored, endorsed, or approved by Merck & Co., Inc.

Free Case Evaluation

Disclaimer | Privacy Policy

Bookmark and Share

Mikal C. Watts

Mikal C. Watts Mikal C. Watts is one of the most successful pharmaceutical lawyers in the country. He has handled many mass torts, including Ortho-Evra, Vioxx, Fen Phen, Rezulin, Zyprexa, and Sulzer hip implants. Mr. Watts leads a team of successful trial lawyers who handle pharmaceutical product liability cases across the country.

Ryan L. Thompson

Ryan L. Thompson Ryan L. Thompson leads the firm's pharmaceutical and medical device litigation department. He serves as the firm's lead counsel for Actos, NuvaRing, DePuy Hips, Transvaginal Mesh, and other torts. Additionally, Ryan was appointed to serve as Co-Lead counsel nationally in the Incretin-Based Therapies MDL by US District Judge Anthony Battaglia for plaintiff's claiming injuries related to Byetta, Januvia, Janumet, and Victoza.
Contact us using our online form, or call us toll-free at 1(800)796-9605.